Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study

被引：0
|
作者：
Meletios Dimopoulos
Michael Wang
Vladimir Maisnar
Jiri Minarik
William Bensinger
Maria-Victoria Mateos
Mihaela Obreja
Julie Blaedel
Philippe Moreau
机构：
[1] National and Kapodistrian University of Athens,School of Medicine
[2] The University of Texas MD Anderson Cancer Center,undefined
[3] Faculty Hospital and Medical Faculty of Charles University in Hradec Kralove,undefined
[4] University Hospital Olomouc,undefined
[5] Medical Faculty of Palacky University Olomouc,undefined
[6] Fred Hutchinson Cancer Research Center,undefined
[7] Hospital Clinico Universitario de Salamanca-IBSAL,undefined
[8] Amgen,undefined
[9] Inc.,undefined
[10] University of Nantes,undefined
来源：
Journal of Hematology & Oncology | / 11卷
关键词：
Clinical research; Clinical trials; Multiple myeloma; Myeloma therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study
    Dimopoulos, Meletios
    Wang, Michael
    Maisnar, Vladimir
    Minarik, Jiri
    Bensinger, William
    Mateos, Maria-Victoria
    Obreja, Mihaela
    Blaedel, Julie
    Moreau, Philippe
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
  • [2] CARFILZOMIB AND LENALIDOMIDE AND DEXAMETHASONE VS LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA: TEMPORARY ANALYSIS OF RESPONSE TO THE HAZARD RATIO FOR PROGRESSION-FREE SURVIVAL
    Maria Victoria, Mateos Manteca
    Meletios, Dimopoulos A.
    Keith, Stewart A.
    Michael, Wang
    Vladimir, Maisnar
    Jiri, Minarik
    William, Bensinger, I
    Dina, Ben-Yehuda
    Vishal, Kukreti
    Mihaela, Obreja
    Sanjay, Aggarwal
    Philippe, Moreau
    Antonio, Palumbo
    HAEMATOLOGICA, 2016, 101 : 27 - 27
  • [3] Overall Survival (OS) of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide and Dexamethasone (Rd): Final Analysis from the Randomized Phase 3 Aspire Trial
    Stewart, A. Keith
    Siegel, David
    Ludwig, Heinz
    Facon, Thierry
    Goldschmidt, Hartmut
    Jakubowiak, Andrzej J.
    Miguel, Jesus F. San
    Obreja, Mihaela
    Blaedel, Julie
    Dimopoulos, Meletios A.
    BLOOD, 2017, 130
  • [4] CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE VS LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA: ANALYSIS OF RESPONSE AND PROGRESSION-FREE SURVIVAL HAZARD RATIO OVER TIME
    Dimopoulos, M. A.
    Stewart, A. K.
    Wang, M.
    Maisnar, V.
    Minarik, J.
    Bensinger, W. I.
    Mateos, M. V.
    Ben-Yehuda, D.
    Kukreti, V.
    Obreja, M.
    Aggarwal, S.
    Moreau, P.
    Palumbo, A.
    HAEMATOLOGICA, 2016, 101 : 83 - 83
  • [5] Effects of Lenalidomide and Dexamethasone Treatment Duration on Survival in Patients With Relapsed or Refractory Multiple Myeloma Treated With Lenalidomide and Dexamethasone
    San-Miguel, Jesus F.
    Dimopoulos, Meletios A.
    Stadtmauer, Edward A.
    Rajkumar, S. Vincent
    Siegel, David
    Bravo, Marie-Laure
    Olesnyckyj, Marta
    Knight, Robert D.
    Zeldis, Jerome B.
    Harousseau, Jean-Luc
    Weber, Donna M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2011, 11 (01): : 38 - 43
  • [6] EFFICACY AND SAFETY BY CYTOGENETIC RISK STATUS: PHASE 3 STUDY (ASPIRE) OF CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE VERSUS LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA
    Avet-Loiseaul, H.
    Fonseca, R.
    Siege, D., I
    Dimopoulos, Ma
    Spicka, I.
    Masszi, T.
    Hajek, R.
    Rosinol, L.
    Garanava-Marinova, V.
    Mihaylavlo, G.
    Maisnar, V.
    Mateos, M. V.
    Wang, M.
    Niesvizky, R.
    Oriol, A.
    Jakubowiak, A.
    Minarik, J.
    Palumbo, A.
    Bensinger, W.
    Kukreti, V.
    Ben-Yehuda, D.
    Tonda, M.
    Obreja, M.
    Moreau, P.
    HAEMATOLOGICA, 2016, 101 : 262 - 263
  • [7] Carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) and early progression during prior therapy: Secondary analysis from the phase 3 study ASPIRE (NCT01080391).
    Ludwig, Heinz
    Dimopoulos, Meletios A.
    Masszi, Tamas
    Spicka, Ivan
    Rocafiguera, Albert Oriol
    Hajek, Roman
    Rosinol, Laura
    Siegel, David Samuel DiCapua
    Mihaylov, Georgi
    Goranova-Marinova, Vesselina
    Rajnics, Peter
    Suvorov, Aleksandr
    Niesvizky, Ruben
    Jakubowiak, Andrzej J.
    Miguel, Jesus San
    Obreja, Mihaela
    Aggarwal, Sanjay
    Moreau, Philippe
    Palumbo, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [8] Effect of carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) by line of therapy: Secondary analysis from an interim analysis of the phase III study ASPIRE (NCT01080391).
    Dimopoulos, Meletios A.
    Stewart, A. Keith
    Rajkumar, S. Vincent
    Masszi, Tamas
    Oriol, Albert
    Hajek, Roman
    Rosinol, Laura
    Siegel, David Samuel DiCapua
    Mihaylov, Georgi
    Goranova-Marinova, Vesselina
    Rajnics, Peter
    Suvorov, Aleksandr
    Niesvizky, Ruben
    Jakubowiak, Andrzej J.
    San Miguel, Jesus F.
    Ludwig, Heinz
    Zojwalla, Naseem J.
    Moreau, Philippe
    Palumbo, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [9] EFFECT OF CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE VS LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA BY LINE OF THERAPY: INTERIM RESULTS FROM THE PHASE 3 ASPIRE STUDY
    Dimopoulos, M. A.
    Stewart, A. K.
    Rajkumar, S. V.
    Masszi, T.
    Spicka, I.
    Oriol, A.
    Hajek, R.
    Rosinol, L.
    Siegel, D.
    Mihaylov, G. G.
    Goranova-Marinova, V.
    Rajnics, P.
    Suvorov, A.
    Niesvizky, R.
    Jakubowiak, A.
    San-Miguel, J.
    Ludwig, H.
    Zojwalla, N.
    Tonda, M.
    Yang, X.
    Moreau, P.
    Palumbo, A.
    HAEMATOLOGICA, 2015, 100 : 151 - 152
  • [10] ECONOMIC EVALUATION OF CARFILZOMIB plus LENALIDOMIDE plus DEXAMETHASONE (KRD) VS LENALIDOMIDE plus DEXAMETHASONE (RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (R/RMM)
    Fonseca, R.
    Panjabi, S.
    Campioni, M.
    Giannopoulou, A.
    Benedict, A.
    Houisse, I.
    Aggarwal, S.
    Jakubowiak, A.
    HAEMATOLOGICA, 2016, 101 : 526 - 526
12345